Entinostat plus MEK inhibitor pimasertib retarded cell growth in TNBC cells and inflammatory breast cancer (IBC) cells, and reduced tumor growth in mice via regulation of NOXA-participated MCL1 degradation (54). Here, MCL1 is linked to inflammatory breast carcinoma.